Page 25 - Read Online

Wu et al. Cancer Drug Resist 2018;1:204-18 I http://dx.doi.org/10.20517/cdr.2018.16 Page 217

NCT00570713. [Last accessed on 3 Dec 2018]
49. Terwisscha van Scheltinga AG, Ogasawara A, Pacheco G, Vanderbilt AN, Tinianow JN, et al. Preclinical efficacy of an antibody-drug
conjugate targeting mesothelin correlates with quantitative 89 Zr-immunoPET. Mol Cancer Ther 2017;16:134-142.
50. Weekes CD, Lamberts LE, Borad MJ, Voortman J, McWilliams RR, et al. Phase I study of DMOT4039A, an antibody-drug conjugate
targeting mesothelin, in patients with unresectable pancreatic or platinum-resistant ovarian cancer. Mol Cancer Ther 2016;15:439-47.
51. Golfier S, Kopitz C, Kahnert A, Heisler I, Schatz CA, et al. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate
cures tumors with heterogeneous target expression favored by bystander effect. Mol Cancer Ther 2014;13:1537-48.
52. Blumenschein GR, Hassan R, Moore KN, Santin A, Kindler HL, et al. Phase I study of anti-mesothelin antibody drug conjugate
anetumab ravtansine (AR). J Clin Oncol 2016;34:2509.
53. Adjei AA, Bekaii-Saab TS, Berlin J, Philip PA, Mercade TM, et al. Phase 1b multi-indication study of the antibody drug conjugate
anetumab ravtansine in patients with mesothelin-expressing advanced or recurrent malignancies. J Clin Oncol 2018;36:TPS2607.
54. Chokshi S, Hochster HS. An open-label, phase II study of intravenous anetumab ravtansine, an anti-mesothelin antibody drug conjugate,
in pretreated mesothelin-expressing advanced pancreatic cancer. J Clin Oncol 2018;36:TPS540.
55. Zhao XY, Subramanyam B, Sarapa N, Golfier S, Dinter H. Novel antibody therapeutics targeting mesothelin in solid tumors. Clin
Cancer Drugs 2016;3:76-86.
56. Birbe R, Palazzo JP, Walters R, Weinberg D, Schulz S, et al. Guanylyl cyclase C is a marker of intestinal metaplasia, dysplasia, and
adenocarcinoma of the gastrointestinal tract. Hum Pathol 2005;36:170-9.
57. Danaee H, Kalebic T, Wyant T, Fassan M, Mescoli C, et al. Consistent expression of guanylyl cyclase-C in primary and metastatic
gastrointestinal cancers. PLoS One 2017;12:e0189953.
58. Schreiber AR, Nguyen A, Bagby SM, Yacob B, Quackenbush K, et al. Abstract B050: evaluation of TAK-264, a novel antibody-drug
conjugate in pancreatic cancer cell lines and patient-derived xenograft models. Mol Cancer Ther 2018;17:B050.
59. Almhanna K, Kalebic T, Cruz C, Faris JE, Ryan DP, et al. Phase I study of the investigational anti-guanylyl cyclase antibody-drug
conjugate TAK-264 (MLN0264) in adult patients with advanced gastrointestinal malignancies. Clin Cancer Res 2016;22:5049-57.
60. Bang YJ, Takano T, Lin CC, Fasanmade A, Yang H, et al. TAK-264 (MLN0264) in previously treated asian patients with advanced
gastrointestinal carcinoma expressing guanylyl cyclase C: results from an open-label, non-randomized phase 1 study. Cancer Res Treat
2018;50:398-404.
61. Almhanna K, Wright D, Mercade TM, Van Laethem JL, Gracian AC, et al. A phase II study of antibody-drug conjugate, TAK-264
(MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Invest
New Drugs 2017;35:634-41.
62. Almhanna K, Miron ML, Wright D, Gracian AC, Hubner RA, et al. Phase II study of the antibody-drug conjugate TAK-264 (MLN0264)
in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C.
Invest New Drugs 2017;35:235-41.
63. Abu-Yousif AO, Bannerman BM, Cvet D, Gallery M, Ganno ML, et al. Abstract B120: TAK-164, a GCC-targeted antibody-drug
conjugate (ADC) for the treatment of colorectal cancers and other GI malignancies. Mol Cancer Ther 2018;17:B120.
64. Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and
metastasis. Cancer Metastasis Rev 2013;32:643-71.
65. Decary S, Berne PF, Nicolazzi C, Lefebvre AM, Dabdoubi T, et al. Abstract 1688: a novel anti-CEACAM5 maytansinoid-antibody-drug
conjugate for the treatment of colorectal, lung and gastric tumors. Cancer Res 2015;75:1688.
66. Gazzah A, Stjepanovic N, Ryu MH, Tabernero J, Soria JC, et al. First-in-human phase I trial of the anti-CEACAM5 antibody-drug
conjugate SAR408701 in patients with advanced solid tumors (NCT02187848). Eur J Cancer 2016;69:S14-5.
67. Govindan SV, Cardillo TM, Rossi EA, McBride WJ, Sharkey RM, et al. IMMU-130, a unique antibody-drug conjugate (ADC) of SN-38
targeting CEACAM5 antigen: pre-clinical basis for clinical activity in metastatic colorectal cancer (mCRC). J Clin Oncol 2015;33:625.
68. Cardillo TM,.Sharkey RM, Govindan SV, Donnel J, Zalath M, et al. Abstract 4081: superior SN-38 pharmacodynamic and tumor-
accretion profiles of labetuzumab govitecan (IMMU-130) versus irinotecan in experimental human colonic cancer models. Cancer Res
2017;77:4081.
69. Govindan SV, Cardillo TM, Moon SJ, Hansen HJ, Goldenberg DM. CEACAM5-targeted therapy of human colonic and pancreatic
cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009;15:6052-61.
70. Segal NH, Dotan E, Berlin JD, Starodub AN, Guarino MJ, et al. Abstract CT211: IMMU-130, an SN-38 antibody-drug conjugate (ADC)
targeting CEACAM5, is therapeutically active in metastatic colorectal cancer (mCRC): initial clinical results of two phase I studies.
Cancer Res 2014;74:CT211.
71. Dotan E, Cohen SJ, Starodub AN, Lieu CH, Messersmith WA, et al. Phase I/II trial of labetuzumab govitecan (anti-CEACAM5/SN-38
antibody-drug conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol 2017;35:3338-46
72. Govindan SV, Cardillo TM, Rossi EA, Trisal P, McBride WJ, et al. Improving the therapeutic index in cancer therapy by using antibody-
drug conjugates designed with a moderately cytotoxic drug. Mol Pharm 2015;12:1836-47.
73. Helft PR, Schilsky RL, Hoke FJ, Williams D, Kindler HL, et al. A phase I study of cantuzumab mertansine administered as a single
intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res 2004;10:4363-8.
74. Kovtun YV, Audette CA, Ye Y, Xie H, Ruberti MF, et al. Antibody-drug conjugates designed to eradicate tumors with homogeneous and
heterogeneous expression of the target antigen. Cancer Res 2006;66:3214-21.
75. Tolcher AW, Ochoa L, Hammond LA, Patnaik A, Edwards T, et al. Cantuzumab mertansine, a maytansinoid immunoconjugate directed
to the CanAg antigen: a phase I, pharmacokinetic, and biologic correlative study. J Clin Oncol 2003;21:211-22.